News

Call for adaptive licensing to smash UK cancer drugs bottle-neck


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Call for adaptive licensing to smash UK cancer drugs bottle-neck

Date: 12/06/2015

The rejection of yet another promising cancer drug by NHS cost regulators has sparked a renewed call for reform of the system and the introduction of adaptive licensing to help speed up patient access to innovative medicines.

The National Institute for Health and Care Excellence has today published draft guidelines rejecting the use of Astellas’ Xtandi (enzalutamide) to treat patients with advanced prostate cancer before chemotherapy.

For more click here

source: PharmaTimes

© Catalyst Innovation Portal 2019